Metoclopramide Injection, Solution
NDC Package 0703-4502-04

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Other Packages
    4. Frequently Asked Questions

Package Information

Metoclopramide injection is metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. This formulation utilizes a injection, solution delivery system. Marketed by Teva Parenteral Medicines, Inc., this product is identified by NDC 0703-4502 and is authorized under FDA application ANDA073135.

Identification & Billing

NDC Package Code
0703-4502-04
Package Description
25 VIAL, SINGLE-USE in 1 TRAY / 2 mL in 1 VIAL, SINGLE-USE (0703-4502-01)
Product Code
0703-4502
11-Digit Billing Format
00703450204
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Metoclopramide
Non-Proprietary Name
Metoclopramide
Substance Name
Metoclopramide Hydrochloride
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
  • Intramuscular - Administration within a muscle.
  • Intravenous - Administration within or into a vein or veins.
  • Intramuscular - Administration within a muscle.
  • Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. Metoclopramide is contraindicated in patients with pheochromocytoma because the drug may cause a hypertensive crisis, probably due to release of catecholamines from the tumor. Such hypertensive crises may be controlled by phentolamine. Metoclopramide is contraindicated in patients with known sensitivity or intolerance to the drug. Metoclopramide should not be used in epileptics or patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of seizures or extrapyramidal reactions may be increased.

Regulatory & Marketing

Labeler Name
Teva Parenteral Medicines, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA073135
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-01-1991
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J2765
Source: PDAC
INJECTION, METOCLOPRAMIDE HCL, UP TO 10 MG
HCPCS Dosage 10 MG
Units / Pkg

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0703-4502). Click a package code to view its specific billing and regulatory data.

0703-4502-84
25 VIAL, SINGLE-USE in 1 TRAY / 2 mL in 1 VIAL, SINGLE-USE (0703-4502-81)
0703-4502-93
10 VIAL, SINGLE-USE in 1 CARTON / 2 mL in 1 VIAL, SINGLE-USE (0703-4502-91)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0703-4502-04 identifies a specific commercial package of 25 vial, single-use in 1 tray / 2 ml in 1 vial, single-use (0703-4502-01) of Metoclopramide, a human prescription drug labeled by Teva Parenteral Medicines, Inc.. This injection, solution is formulated for intramuscular; intravenous use and contains metoclopramide hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Teva Parenteral Medicines, Inc. on December 01, 1991. The current certification is valid through December 31, 2027.

How is this Teva Parenteral Medicines, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00703450204. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0703-4502-04
11-Digit CMS (5-4-2)
00703-4502-04

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.